The CHMP Pharmacovigilance Working Party (PhVWP) was responsible for evaluating and monitoring safety issues for human medicines until 2012; it was then replaced by the Pharmacovigilance Risk Assessment Committee (PRAC) with the entry into force of Directive 2010/84/EU. PhVWP recommendation
